72754-01-9

Usage

Uses

Used in Pharmaceutical Industry:
1,4-Dihydro-1,6-naphthyridin-4-one is used as a key intermediate in the synthesis of various pharmaceuticals for its potential biological activity. It has shown promise as an inhibitor of certain enzymes, which can be utilized in the development of drugs targeting specific biological pathways.
Used in Cancer Treatment Research:
In the field of oncology, 1,4-Dihydro-1,6-naphthyridin-4-one is studied for its potential role in the treatment of various types of cancer. Its ability to inhibit specific enzymes may contribute to the development of novel therapeutic agents that can target cancer cells and inhibit their growth and proliferation.
Used in Antibacterial Agents Development:
1,4-Dihydro-1,6-naphthyridin-4-one has also demonstrated potential in the treatment of bacterial infections. Its chemical properties and reactivity make it a candidate for the development of new antibacterial agents that can combat drug-resistant bacteria and provide alternative treatment options.
Used in Chemical Reactions:
Furthermore, 1,4-Dihydro-1,6-naphthyridin-4-one has been tested for its chemical reactivity, showing promising results in various chemical reactions. This makes it a valuable compound for use in the synthesis of other complex organic molecules and in the development of new chemical processes and applications.

Upstream product

• 504-24-5 4-aminopyridine 
• 863785-65-3 5-[[(2,6-dichloropyridin-4-yl)amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 92310-23-1 4-oxo-1,4-dihydro-[1,6]naphthyridin-3-yl carboxylic acid ethyl ester 
• 4901-94-4 4-oxo-1,4-dihydro-[1,6]naphthyridine-3-carboxylic acid 

Downstream Products

• 6861-84-3 4-chloro-[1,6]naphthyridine 

Relevant academic research and scientific papers

NEW [1,6]NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS

The present invention encompasses compounds of formula (I) wherein the groups R1 to R5, A and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

Gas-phase pyrolysis in organic synthesis: Rapid green synthesis of 4-quinolinones

Gas-phase pyrolysis of aminomethylene Meldrum's acid derivatives gave quinolinones and/or amines depending on the nature of arylamino moiety. Effect of substituent on reaction rate and nature of pyrolysis products supports the suggested intramolecular nucleophilic substitution reaction via initially formed keteneamine intermediate. Georg Thieme Verlag Stuttgart.

COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides compounds of formula (I) or compounds of formula (II) and pharmaceutically acceptable salts or solvates thereof. An objective of the present invention is to provide compounds having TGF2 inhibitory activity.

ANTIBACTERIAL COMPOUNDS

Cyclohexane and cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man